Goldline Pharmaceutical's Q2 FY27 net profit surged 50.7% year-on-year, driven by a sharp reduction in interest expenses following a major debt repayment funded by fresh equity.
Goldline Pharmaceutical's Q2 FY27 profit jumped 51% year-on-year to ₹2.05 crore, even as revenue grew modestly. The profit surge was fueled by a 58% drop in interest costs after the company used fresh equity to repay debt.
For a small pharmaceutical marketer, the cost of capital often dictates the bottom line. Goldline Pharmaceutical's September quarter delivered a clear win on that front, with profit soaring over 50% on a modest sales increase as a heavy debt burden lifted.
The numbers show a company in transition. Revenue for Q2 FY27 was ₹14.93 crore, up 7.5% from a year ago but down 13.7% sequentially. Net profit, however, leapt to ₹2.05 crore, a 50.7% year-on-year gain. The net profit margin expanded to 13.7%, a significant 390 basis point improvement from Q2 FY26.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Revenue (₹ Cr) | 14.93YoY +7.5% | 13.89 |
| Profit (₹ Cr) | 2.05YoY +51% | 1.36 |
| Net Profit Margin (%) | 13.7YoY +40% | 9.8 |
The primary driver of the profit jump was a dramatic fall in finance costs. According to a report from mcapital.in, the company repaid about ₹8.5 crore of debt using ₹11.61 crore raised from a fresh equity issue. This slashed interest expense by 58.2% year-on-year to just ₹0.28 crore, directly boosting the bottom line.
This financial engineering has fundamentally strengthened the balance sheet. The same report notes net worth nearly doubled to about ₹25.9 crore, while debt was drastically reduced. The trade-off, however, is earnings dilution from the increased share capital.
While the annual comparison is positive, the quarter-on-quarter picture is softer. Revenue fell from ₹17.31 crore in the March 2026 quarter. The research did not pinpoint a specific cause, but the broader domestic pharmaceutical market, as reported by Business Standard, showed robust 13.5% value growth in September, driven by both price and volume.
Live Chart
· GLPL
(BSE)
ISIN: INE1CLW01015
For Goldline, operating performance faced some pressure. Employee costs rose 34% year-on-year, according to mcapital.in, squeezing the operating margin. Furthermore, operating cash flow was a meagre ₹0.11 crore for the half-year, as a ₹2.59 crore working capital outflow, led by rising receivables, absorbed profits.
Key Points
The quarter tells a story of successful balance sheet repair over operational outperformance. The equity-funded debt repayment has created a cleaner, stronger platform for growth by removing a major cost drag. The challenge now is conversion.
Growth must come from the top line and better working capital management to turn accounting profits into cash. With a fortified equity base and minimal debt, the company has the stability to pursue this, but the recent sequential sales dip and stretched receivables show the path ahead is not automatic.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.